Day: May 21, 2024

Paris, 21 May 2024, 8:50 a.m. PRESS RELEASE Eramet: Launch of an any and all cash tender offer to repurchase its bonds due May 2025 and potential issuance of new sustainability-linked bonds Eramet (the “Company”) announces today: (i)      the launch of a tender offer to repurchase for cash any and all of its €300 million bonds due May 2025 issued on 21 November 2019 (ISIN: FR0013461274), of which € 293,600,000 are currently outstanding, and which are admitted to trading on the regulated market of Euronext Paris (the “Existing Bonds”) (the “Tender Offer”); and (ii)      its intention, subject to market conditions, to issue new sustainability-linked bonds denominated in euros concomitantly with the Tender Offer (the “New Bonds”). The Tender Offer is made under the terms and conditions set out in the Tender Offer Memorandum dated 21 May...

Luxembourg – 21 May 2024 – Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced transactions made in accordance with its share repurchase programme during the week commencing 13 May 2024.                                                 Date on which the share repurchase programme was announced: 25 July 2019, with a two-year extension announced on 19 April 2023. The duration of the share repurchase programme: until 18 April 2025.                                                        In the period from 13 May 2024 until 16 May 2024 Subsea 7 S.A. has repurchased a total of 228,500 own shares at the Oslo Stock Exchange at an average price of NOK 187.2265 per share.                                                                                                        Overview of transactionsDates Aggregated daily volume(number...

Company Announcement No 18/2024 Peberlyk 46200 AabenraaDenmarkTel +45 74 37 37 37 Sydbank A/SCVR No DK 12626509, Aabenraasydbank.dk21 May 2024  Dear Sirs Sydbank to acquire Coop Bank A/S Sydbank A/S and Coop amba have concluded an agreement to the effect that Sydbank will acquire Coop Bank A/S. Following the acquisition, Coop Bank A/S will become a wholly owned subsidiary of Sydbank A/S. In addition the agreement includes a partnership that will create attractive value propositions for the customers of Coop Bank A/S as well as for the other members of Coop Danmark. It is expected that the partnership will generate increased business volume at Coop Bank A/S. Purchase priceThe parties have agreed a price involving payment of the value of the equity at the date of acquisition plus DKK 89m. The cash purchase price cannot be finally...

Q1 2024 revenue Strong start of the year anddynamic commercial momentumTotal revenue growth of +19.6% in constant currencies, reaching € 40.9 million Solid commercial traction with existing clients and new logos Further product enhancements and third-party industry analysts’ recognition 2024 objectives confirmedParis, France, May 21, 2024 – Planisware, a leading B2B provider of SaaS in the rapidly growing Project Economy market, announces today its revenue for Q1 2024. Total revenue amounted to € 40.9 million, up by +18.5% in current currencies, mainly led by the continued success of the Group’s market-leading SaaS platform. In constant currencies, total revenue growth reached +19.6% (+€6.8 million), in line with the trajectory expected for the year and the 2024 objective of approximately 19.5% revenue growth in constant currencies....

The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting1 Approximately 40% of people with HR-positive breast cancer have a PIK3CA mutation and often face poorer prognosis and resistance to endocrine treatment2,3 This is the 29th Breakthrough Therapy Designation for Roche’s oncology portfolio, a testament to our enduring ambition to deliver transformative medicines for patients4Basel, 21 May 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for inavolisib, an investigational oral therapy, in combination with palbociclib (Ibrance®) and fulvestrant, for the treatment of adult...

Ad hoc announcement pursuant to Art. 53 LRJean-Paul Clozel to retire as CEO and stand for election as Chairman of the Board of Directors Mathieu Simon to stand for re-election to the Board – taking on the role of Vice-Chairman and Lead Independent Director André C. Muller, current CFO of Idorsia, to take over the role of CEO as of June 13, 2024Allschwil, Switzerland – May 21, 2024Idorsia Ltd (SIX: IDIA) today announced changes to the Idorsia Executive Committee (IEC) and will propose changes in membership of the Board of Directors at the upcoming Annual General Meeting of shareholders (AGM), to be held on June 13, 2024. Jean-Paul Clozel, 69, has decided to retire from his role as Chief Executive Officer (CEO) of Idorsia and stand for election as Chairman of the Board of Directors at this year’s AGM. Jean-Paul has served as CEO of Idorsia...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – May 21, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2024. Business highlightsViatris collaboration: Global research and development collaboration, focused on the development and commercialization of two innovative compounds, selatogrel and cenerimod.Commercial highlightsQUVIVIQ™ (daridorexant): Total net sales of CHF 10 million in Q1 2024. QUVIVIQ in the US: Citizens petition to deschedule the DORA class progressing. QUVIVIQ in Europe: Further launches, including France, provide a solid base to increase European sales in 2024.Pipeline highlightsTRYVIO™ (aprocitentan): Approved by the US FDA in March 2024. JERAYGO™ (aprocitentan): Recommended for approval in Europe. Daridorexant: Phase 3 study...